Prospective study on peripheral and intrahepatic immune cells derived from chronic hepatitis B patients during and after long-term treatment with direct antivirals - HBV-FNAB-002 study

Start Date10 Mar 2020

Sponsor / Collaborator-

100 Clinical Results associated with Antivirals(Healion Bio)

100 Translational Medicine associated with Antivirals(Healion Bio)

100 Patents (Medical) associated with Antivirals(Healion Bio)

793

Literatures (Medical) associated with Antivirals(Healion Bio)

01 Apr 2025·Research in Social and Administrative Pharmacy

The role of community pharmacists in point-of-care testing and treatment for influenza and Group A Streptococcus -a narrative review using Ecological Systems Theory

Review

Author: Witry, Matthew

BACKGROUNDPoint-of-care testing (POCT) is a valuable diagnostic approach for identifying pathogens such as Group A Streptococcus (GAS) and influenza. Early detection through POCT allows for timely initiation of appropriate treatments improving public health outcomes and minimizing antibiotic misuse. Community pharmacists are well positioned to offer POCT and treatment, but they face significant system level barriers to widespread implementation and reach.METHODSThis narrative review employs Ecological Systems Theory to examine the role of community pharmacists in the implementation of POCT and subsequent treatment for respiratory infections and synthesize findings from a range of studies at different levels of the system. Medline was used to identify articles with MESH headings of rapid diagnostic tests and community pharmacists. Articles were reviewed and used to inform the synthesis. Additional articles were identified using free-text search to fill gaps in the domains.RESULTSThe review indicates that community pharmacists are well-positioned to provide POCT for respiratory infections, addressing barriers such as appointment availability, scheduling difficulties, and distance to primary care facilities. The accessibility of neighborhood pharmacies can significantly reduce health disparities by offering timely testing and treatment options. Studies demonstrate that early intervention facilitated by POCT in pharmacies leads to better health outcomes and more efficient use of antibiotics and antivirals.CONCLUSIONSCommunity pharmacists play a crucial role in expanding access to POCT and treatment for respiratory infections, particularly in underserved areas. Their involvement can lead to improved public health outcomes by ensuring early and appropriate treatment. Future research should focus on overcoming barriers to POCT implementation in pharmacies and further quantifying the impact on health disparities and treatment efficacy. The integration of POCT services in community pharmacies represents a significant advancement in public health strategy, enhancing the overall healthcare delivery system.

01 Mar 2025·Otolaryngology–Head and Neck Surgery

Analysis of Adherence to AAO‐HNSF Clinical Practice Guidelines for Sudden Hearing Loss

Article

Author: Eberly, Hänel W. ; Rothka, Andrew J. ; Goyal, Neerav ; Sciscent, Bao Y. ; Lorenz, F. Jeffrey ; Whitaker, Mark E.

AbstractObjectiveTo assess adherence to the 2019 American Academy of Otolaryngology‐Head and Neck Surgery (AAO‐HNSF) guidelines for the diagnosis and management of sudden hearing loss (SHL) and sudden sensorineural hearing loss (SSNHL).Study DesignRetrospective cohort.SettingTriNetX, a de‐identified healthcare database.MethodsEvaluation focused on the percentage of patients undergoing proper guideline‐adherent workup and treatment for SHL. Key measures include audiogram testing within 2 weeks for distinguishing SSNHL from CHL. For SSNHL patients, MRI or auditory brainstem response (ABR) testing should be obtained, and steroids and/or hyperbaric oxygen may be offered within 2 weeks.ResultsThere were 24,203 SHL patients, 59.1% (n = 14,309) of whom underwent recommended audiogram testing, with 35.8% (n = 8,674) completing it within 2 weeks. Overall, 3,107 were diagnosed with unilateral SSNHL, 104 with unilateral conductive hearing loss (CHL), 121 with mixed hearing loss, and 10,977 were lost to follow‐up. Among 3,107 SSNHL cases, just 25.5% (n = 791) obtained MRI/ABR within 1 month, and vestibular schwannoma was diagnosed in 3.5% (n = 28). Additionally, steroids were prescribed to 54.5% (n = 1,692), and <0.3% (n ≤ 10) received hyperbaric oxygen. In accordance with strong recommendations against or insufficient evidence to support the following diagnostics and treatments, 2.0% (n = 63) underwent a CT scan, less than 0.3% (n ≤ 10) were prescribed vasodilators or thrombolytics, and 3.5% (n = 108) were on antivirals.ConclusionThere is a significant opportunity for improvement in evaluating patients with SHL, specifically SSNHL. Proper adherence to guidelines may improve screening, detection, and management of neurotologic pathologies, including vestibular schwannoma.

01 Mar 2025·Journal of Internal Medicine

Incidence and predictors of clinical failure after early treatment for mild‐to‐moderate COVID‐19 in high‐risk individuals: A multicentric cohort study

Article

Author: Antinori, Andrea ; Mazzotta, Valentina ; Mastrorosa, Ilaria ; Girardi, Enrico ; Maggi, Fabrizio ; Nicastri, Emanuele ; Mastroianni, Claudio ; Borgo, Cosmo Del ; Lichtner, Miriam ; Sarmati, Loredana ; Rueca, Martina ; Rosati, Silvia ; Fantoni, Massimo ; Lepri, Alessandro Cozzi

AbstractObjectivesTo estimate the risk of COVID‐19‐related hospitalization and death (CovH/D), among high‐risk individuals early treated for COVID‐19 and to identify associated factors.Methods and resultsA multicenter cohort of 12,475 high‐risk outpatients (female 50.2%, median age 70 years [IQR 57–80], fully vaccinated 79.1%, immunocompromised 23.2%) treated with monoclonal antibodies or antivirals for mild‐to‐moderate COVID‐19 (March 2021–May 2023) in the Lazio region, Italy. The unadjusted risk of CovH/D by Day 30 was 3.08% (95% CI 2.7%–3.4%). By means of logistic regression models, which included a specific set of potential confounders for each exposure of interest, we observed a higher risk for the elderly, unvaccinated and immunocompromised participants. Using the “Delta period” as a reference, a decreased risk was observed for Omicron waves.ConclusionsDespite the administration of COVID‐19 early treatment and the decreasing risk of CovH/D across the calendar periods, the elderly, the unvaccinated and the immunocompromised people remain at high risk of clinical progression.

100 Deals associated with Antivirals(Healion Bio)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Discovery	United States	Healion Bio, Inc.	01 Apr 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Antivirals(Healion Bio)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation